GlassScriptPhysician profile
Matthew T Crooks
NPI 1609914662
$20,838.81
in general payments reported to CMS, 2019-2025
27 companies · $2,617 in 2025
The $2,617 reported for 2025 was more than what 84% of Pain Medicine providers received nationally (typical 2025 total: $515).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,598 · 2020: $2,873 · 2021: $5,949 · 2022: $3,111 · 2023: $1,953 · 2024: $1,738 · 2025: $2,617.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,908 · Consulting Fee: $400.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,908.30 |
| Consulting Fee | $400.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $14,933.20 | 2019-2025 | Proclaim, Eterna, Octrode |
| Medtronic, INC. | $1,086.62 | 2021-2025 | Intellis Adaptivestim, Inceptiv, Aquamantys(Tm) |
| Vertiflex, INC. | $875.68 | 2019 | |
| Boston Scientific Corporation | $797.60 | 2020-2025 | Intracept, Na, Superion Indirect Decompression System |
| Lenoss Medical INC | $727.80 | 2024-2025 | Osteopearl, Access & Cavity Creation Kit |
| Medtronic USA, INC. | $478.23 | 2019-2020 | |
| Nevro Corp. | $385.76 | 2019-2024 | Senza |
| Nalu Medical, INC. | $313.51 | 2021-2025 | Nalu Neurostimulation System |
| Bioventus LLC | $226.94 | 2025 | |
| Saluda Medical Americas, INC. | $220.87 | 2023-2025 | Evoke, Evoke Scs |
| Arteriocyte Medical Systems, INC. | $159.00 | 2023 | Magellan |
| Life Spine, INC. | $127.51 | 2022 | |
| Xtant Medical INC | $92.73 | 2025 | |
| Spr Therapeutics, INC | $79.01 | 2019-2022 | |
| Relievant Medsystems, INC. | $58.94 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Painteq LLC | $58.65 | 2023-2024 | Painteq |
| Biotronik Nro, INC. | $56.31 | 2024-2025 | Prospera |
| Foundation Fusion Solutions, LLC | $30.49 | 2023-2024 | |
| Pacira Pharmaceuticals Incorporated | $25.96 | 2023 | Iovera |
| Pacira Therapeutics, INC. | $21.11 | 2019 | |
| Galen US INC | $20.14 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $19.99 | 2025 | |
| Radius Health, INC. | $16.32 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.53 | 2023 | Relistor |
| Collegium Pharmaceutical, INC. | $11.91 | 2022 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Crooks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.